Both systems depend on NADPH as their primary electron donor, making NADPH a central metabolic link between antioxidant mechanisms and overall cellular pathways
Earlier versions required strict timing and fasting conditions, which made adherence challenging
once-daily products need gradual schedule adjustment for time zone changes
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
At 52 weeks, the semaglutide group showed a statistically significant reduction in areal bone mineral density at the total hip (estimated treatment difference: -0.020 g/cm, p = 0.001, equating to approximately 2.6% loss) and at the lumbar spine (ETD: -0.018 g/cm, p = 0.007, approximately 2.1% loss)
